Penicillin-Susceptible Group B Streptococcal Clinical Isolates with Reduced Cephalosporin Susceptibility

Nagano, Noriyuki; Nagano, Yukiko; Toyama, Masami; Kimura, Kouji; Shibayama, Keigo; Arakawa, Yoshichika

doi:10.1128/jcm.01291-14

Cited by 26 publications

(14 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the molecular and genetic aspects of PRGBS and some GBS isolates with augmented cephalosporin MICs, Nagano and Kimura, as well as their collaborators, found further amino acid substitutions in PBPs, including PBP2X, together with their genetic varieties. 69,70 With the increase in reports about S. agalactiae showing reduced susceptibility or resistance to penicillins and/or cephalosporins, we proposed a practical protocol and criteria for the classification of GBS demonstrating reduced β-lactam susceptibility. 71 As a matter of note about PRGBS, almost all the clinical PRGBS isolates in Japan tend to show MDR to fluoroquinolones and macrolides, 72 and they are usually serotype IV and ST458 belonging to the clonal complex 1 (CC1).…”

Section: Streptococcus Agalactiae With Reduced Susceptibility To Pementioning

confidence: 99%

Systematic research to overcome newly emerged multidrug‐resistant bacteria

Arakawa

2020

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

In the 1980s, I found that the chromosomal β-lactamase of Klebsiella pneumoniae LEN-1 showed a very high similarity to the R-plasmid-mediated penicillinase TEM-1 on the amino acid sequence level, and this strongly suggested the origination of TEM-1 from the chromosomal penicillinases of K. pneumoniae or related bacteria. Moreover, the chromosomal K1 β-lactamase (KOXY) of Klebsiella oxytoca was found to belong to the class A β-lactamases that include LEN-1 and TEM-1, although KOXY can hydrolyze cefoperazone (CPZ) like the chromosomal AmpCtype cephalosporinases of various Enterobacteriaceae that can hydrolyze several cephalosporins including CPZ. Furthermore, my collaborators and I found plural novel serine-type β-lactamases, such as MOX-1, SHV-24, TEM-91, CTX-M-64, CMY-9, CMY-19, GES-3, GES-4, and TLA-3, mediated by plasmids. Besides these serine-type β-lactamases, we also first identified exogenously acquired metalloβ-lactamases (MBLs), IMP-1 and SMB-1, in imipenem-resistant Serratia marcescens, and the IMP-1-producing S. marcescens TN9106 became the index case for carbapenemase-producing Enterobacteriaceae. I developed the sodium mercaptoacetic acid (SMA)-disk test for the simple identification of MBL-producing bacteria. We were also the first to identify a variety of plasmid-mediated 16S ribosomal RNA methyltransferases, RmtA, RmtB, RmtC, and NpmA, from various Gram-negative bacteria that showed very high levels of resistance to a wide range of aminoglycosides. Furthermore, we first found plasmid-mediated quinolone efflux pump (QepA) and fosfomycin-inactivating enzymes (FosA3 and FosK).We also first characterized penicillin reduced susceptible Streptococcus agalactiae, macrolide-resistant Mycoplasma pneumoniae, as well as Campylobacter jejuni, and Helicobacter pylori, together with carbapenem-resistant Haemophilus influenzae.---

show abstract

Section: Streptococcus Agalactiae With Reduced Susceptibility To Pementioning

confidence: 99%

Systematic research to overcome newly emerged multidrug‐resistant bacteria

Arakawa

2020

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite GBS being mostly considered susceptible to penicillin, the first-line antibiotic for prophylaxis and treatment of GBS disease, occasional reports of reduced susceptibility associated with mutations in the penicillin-binding proteins have been published, raising concern as to the possible emergence of β-lactam resistance [7]. Erythromycin and clindamycin have been recommended as second-line drugs for patients allergic to β-lactams, but in recent years increasing macrolide and lincosamide resistance is being reported worldwide [4,8,9].…”

Section: Introductionmentioning

confidence: 99%

Changing epidemiology of group B streptococcal infections among adults in Iceland: 1975–2014

Björnsdóttir

Martins

Erlendsdóttir

et al. 2016

Clinical Microbiology and Infection

View full text Add to dashboard Cite

We studied the bacterial characteristics and incidence of invasive infections caused by group B streptococci (GBS) in adults in Iceland in 1975-2014. A total of 145 isolates were characterized by serotyping, antimicrobial susceptibility, multilocus sequence typing and surface protein gene profiling. Disease incidence increased during the studied period (p <0.001), reaching 2.17 cases/100 000 person-years in 2013-14. Overall, serotype Ia was the most frequently found (23%), but serotypes Ib, II, III and V showed similar prevalence (14%-17%). Although there were notable changes in the proportion of most serotypes during the study period, only the decline of serotype III was statistically supported (p = 0.003) and was reflected in a decrease of clonal complexes CC17 and CC19 that included most serotype III isolates (p <0.04). On the other hand, the increase in frequency of CC1 was caused by two lineages expressing distinct serotypes: ST1/V/alp3 and ST196/IV/eps. Underlying the relative stability of serotype Ia were major changes in the lineages expressing this serotype, with an increase in the relative importance of CC23, including both ST23/Ia/eps and ST24/Ia/bca lineages, and a decrease in CC7. Nine cases of invasive GBS disease were caused by ST7, of possible zoonotic origin. All isolates were susceptible to penicillin. Rates of erythromycin and clindamycin resistance were 8.3% and 9.7%, respectively. An over-representation of resistance solely to clindamycin was associated with the unusual lsaC gene and serotype III ST19/rib lineage (p <0.001).

show abstract

“…However, only 81.6% specificity was achieved. This apparent lack of specificity was likely due to the presence of PSGBS with reduced cephalosporin susceptibility (MRY09-31 and MRY09-34), as reported previously (Nagano et al, 2014). These clinical isolates harbor unique amino acid substitutions in PBP2X and show penicillinsusceptible and ceftibuten-nonsusceptible phenotypes.…”

Section: Discussionmentioning

confidence: 68%